The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is one of the most critical and extensively investigated signaling pathways. It is the central regulator of various cellular processes ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Gastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide, with its aggressive metastatic ...
Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer. This is an ASCO Meeting Abstract from the 2026 ...
Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...
PI3K signaling pathways. Upon activation by RTK, GPCR, Integrin, and Ras, p110 loses inhibition by p85 and converts PIP2 to PIP3. PIP3 recruits AKT to the cell membrane, where AKT is activated through ...
REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In ...
Approval is backed by VIKTORIA-1 (PIK3CA wild-type), a global open-label randomized trial of gedatolisib plus fulvestrant ± palbociclib after progression on CDK4/6 therapy and an aromatase inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results